期刊文献+

Ⅲ期Ⅳ期非小细胞肺癌预后影响因素分析 被引量:17

Prognostic factors in patients with stage III and IV non-small cell lung cancer
原文传递
导出
摘要 目的 研究Ⅲ、Ⅳ期非小细胞肺癌 (NSCLC)患者的预后相关因素 ,建立具有临床实用性的预后模型。方法 采用Kaplan Meier和Cox回归方法分析 114例NSCLC患者治疗前血清神经元特异性烯醇化酶 (NSE)、癌胚抗原 (CEA)、Cyfra2 1 1、CA12 5、IL 2、sIL 2R等 6种肿瘤标记物的水平及常规临床因素 ,如年龄、性别、吸烟指数、KPS评分、临床分期等与生存率的关系。结果 单因素分析表明 ,临床分期、KPS评分、性别以及治疗前血清Cyfra2 1 1和CA12 5水平与NSCLC患者生存率有关。多因素分析表明 ,Cyfra2 1 1、临床分期及治疗情况是独立的预后影响因素 ,Cyfra2 1 1>3.5mg/L、临床分期为Ⅳ期、治疗少于 3周期时 ,相对危险性 (RR)分别为 1.6 91,2 .2 2 9和 3.0 35。化疗 3周期及以上的患者 ,Cyfra2 1 1、sIL 2R及临床分期是独立的预后影响因素。建立患者治疗前的预后指数 (PI)模型 :PI =Cyfra2 1 1+sIL 2R +Stage。化疗 3周期及以上者 ,PI=0时 ,中位生存期 18个月 ;PI=1或 2时为 8个月 ,PI =3时为 5个月。结论 治疗前血清Cyfra2 1 1、sIL 2R和临床分期 ,是Ⅲ、Ⅳ期NSCLC患者独立的预后影响因素。采用患者治疗前血清Cyfra2 1 1、sIL 2R及临床分期建立的预后指数模型有实际应用价值。 Objective To investigate the prognostic factors in non small cell lung cancer (NSCLC) at stage Ⅲ and Ⅳ and establish a reliable model of clinical prognostic index. Methods Kaplan Meier and Cox regression were used to analyze the relationship between the prognostic factors and survival time in 114 cases of NSCLC. The prognostic factors included clinical pathological features and serum levels of cytokeratin fragment 19 (Cyfra21 1), CEA, neuron specific enolase (NSE), CA125, interleukin 2(IL 2) and soluble interleukin 2 receptors (sIL 2R). Results Kaplan Meier analysis showed that KPS, sex, disease stage, treatment, Cyfra21 1, sIL 2R and CA125 were related to prognosis. Multivariate analysis indicated that Cyfra21 1, stage and treatment were independent prognostic factors. When Cyfra21 1>3.5 mg/L, stage Ⅳ and chemotherapy < 3 cycles, the relative risk ( RR ) was 1.691, 2.229 and 3.035, respectively. In patients given 3 or more cycles of chemotherapy, serum Cyfra21 1, sIL 2R and stage at diagnosis were significantly independent prognostic factors. Three of these prognostic factors were used to establish a prognostic index (PI) model based on a simple algorithm: PI = Cyfra21 1 + sIL 2R + stage. The median survival period of patients with 3 or more cycles of chemotherapy were 18 months if PI=0, 8 months if PI=1 or 2, and 5 months if PI=3. Conclusion The serum Cyfra21 1, sIL 2R and disease stage in unresectable NSCLC were independent prognostic factors. PI calculated on the basis of Cyfra21 1, sIL 2R and stage is recommended to predict the survival period of NSCLC.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2004年第6期345-348,共4页 Chinese Journal of Oncology
关键词 Ⅲ期 Ⅳ期 非小细胞肺癌 NSCLC 肿瘤标记物 癌胚抗原 细胞角蛋白19片段 Carcinoma/non-small-cell lung Prognosis Tumor markers/biology Carcinoembryonic antigen Antigen Cyfra21-1
  • 相关文献

参考文献11

  • 1Mountain CF. Staging classification of lung cancer: a critical evaluation. Clin Chest Med, 2002, 23: 103-121.
  • 2Kulpa J, Wojcik E, Reinfuss M, et al. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem, 2002, 48: 1931-1937.
  • 3Foa P, Fornier M, Miceli R, et al. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Int J Biol Markers, 1999,14:92-98.
  • 4Wieskopf B, Demangeat C, Purohit A, et al. Cyfra 21-1 as a biologic marker of non-small cell lung cancer: evaluation of sensitivity, specificity, and prognostic role. Chest,1995,108:163-169.
  • 5Foa P, Fornier M, Miceli R, et al. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res, 1999,19:3613-3618.
  • 6Hirashima T, Takada M, Komiya T, et al. Prognostic significance of CYFRA 21-1 in non-small cell lung cancer.Anticancer Res, 1998,18:4713-4716.
  • 7Nisman B, Amir G, Lafair J, et al. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res, 1999,19:3549-3552.
  • 8Vinolas N, Molina R, Galan MC, et al. Tumor markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report. Anticancer Res,1998, 18:631-634.
  • 9Yeh JJ, Liu FY, Hsu WH, et al. Monitoring cytokeratin fragment 19 (CYFRA 21-1) serum levels for early prediction of recurrence of adenocarcinoma and squamous cell carcinoma in the lung after surgical resection. Lung, 2002,180:273-279.
  • 10De Vita F, Turitto G, di Grazia M, et al. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer. Tumori, 1998,84:33-38.

同被引文献164

引证文献17

二级引证文献127

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部